Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Jan 18, 2024

BUY
$5.63 - $8.27 $5,630 - $8,270
1,000 Added 6.25%
17,000 $115,000
Q3 2023

Oct 26, 2023

BUY
$6.71 - $11.83 $107,360 - $189,280
16,000 New
16,000 $107,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $230M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Clear Harbor Asset Management, LLC Portfolio

Follow Clear Harbor Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clear Harbor Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clear Harbor Asset Management, LLC with notifications on news.